Peptide library / Digestive & weight / Efpeglenatide
Efpeglenatide
A long-acting GLP-1 receptor agonist that showed heart and kidney benefit in a large trial.
Effects studied or claimed
What it is used or promoted for, and where each effect has actually been seen
- Fewer major heart events in type 2 diabetesLarge trials
- Weight loss in obesityLarge trials
How it is thought to work
Efpeglenatide is an exendin-based GLP-1 agonist attached to an antibody fragment, which allows weekly or less frequent dosing.
What the evidence shows
The AMPLITUDE-O trial found fewer cardiovascular events than placebo in people with type 2 diabetes. Sanofi returned the rights to Hanmi, which is developing it for obesity.
Safety and unknowns
Gastrointestinal effects are the most common.
Regulatory status
Not approved by the FDA. Being developed by Hanmi, mainly in Korea.
Regulatory status changes quickly. This entry was last reviewed on 27 October 2026. Confirm current status with the FDA before relying on it.
More in Digestive & weight
Eloralintide
In clinical trialsAn investigational amylin receptor agonist from Eli Lilly in development for obesity.
Exenatide
FDA-approvedThe first GLP-1 receptor agonist, derived from a hormone found in Gila monster saliva.
Ecnoglutide
In clinical trialsAn investigational weekly GLP-1 receptor agonist developed in China by Sciwind Biosciences.
General information, not medical advice. Do not buy or inject unregulated peptides.